Data Supplement for Skovlund et al., Association of Hormonal Contraception With Suicide Attempts and Suicides. Am J Psychiatry (doi: 10.1176/appi.ajp.2017.17060616)

## **Contents**

Table S1. Articles on hormonal contraception and suicide	2
Table S2. Included groups of hormonal contraception and corresponding ATC codes	3
<b>Table S3.</b> Included diagnoses of suicide an suicide attempt according to the international Statistical Classifications of Diseases and Related Health Problems Tenth Revision (ICD10)	4
<b>Table S4.</b> Included diagnoses of venous thromboses from the international Statistical           Classifications of Diseases and Related Health Problems Eight and Tenth Revision	5
Figure S1. Women fulfilling various inclusion and exclusion criteria	6
<b>Figure S2.</b> Lexis-diagram: a cohort of women followed from the age of 15 through the period 1996 to 2013.	7
Table S5. Hazard ratio of a first suicide attempt according to use of different types of hormona         contraception	
<b>Table S6.</b> Hazard ratio of a first suicide attempt according to use of different types of hormona contraception with 30-40 μg levonorgestrel as reference and of progestogen only pills with all oral combined as reference.	
<b>Figure S3.</b> Quantitative bias analysis: Hazard Ratio(HR) of suicide attempt as a function of the odds ratio of being a user of hormonal contraception, for prevalence of 33% of an unknown confounder in the population.	.10

TABLE S1. Articles on hormonal contraception and suicide

Author	Study	Expo-						Results
Year	design	sure	Reference	Population	Age	<b>Events</b>	Persons-years	Risk of suicide
<b>Vessey</b> <sup>1</sup> 1989 England	Cohort	ОС	Diaphragm or IUD	Married women Visiting family planning clinics	25–39*	16	272,512 1968–1986	1.1 (0.3–3.6) No significant difference
<b>Beral<sup>2</sup></b> 1999 Britain	Cohort	ОС	Never use	Women from general practices	29*	55	853,571 1968–1993	1.5 (0.8–2.3) No significant difference
Colditz³ 1994 USA	Cohort	ОС	Never use	Nurses Health study	30–55*	114	1,300,000 1976–1988	1.32 (0.87–1.98) No significant difference
<b>Hannaford⁴</b> 2010 UK	Cohort	ОС	Never use	Married women or living as married	29*	67	1,197,181 1968–2007	1.26 (0.73–2.18) No significant difference
<b>Charlton⁵</b> 2014 USA	Cohort	ОС	Never use	Nurses Health study	30–55	241	3.6 mil	1.41 (1.05–1.87) Significantly increased

OC=Oral contraceptives; IUD=Intrauterine device. \*Mean age at recruitment.

- 1. Vessey MP, Villard-Mackintosh L, McPherson K, et al: Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. BMJ 1989; 299:1487–1491.
- 2. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318:96-100.
- 3. Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study. Ann Intern Med. 1994;120:821-6.
- Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927.
- 5, Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, Speizer FE, Michels KB. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study. BMJ 2014;349:g6356

TABLE S2. Included groups of hormonal contraception and corresponding ATC codes

Hormonal						
contraception group§	ATC codes*					
Combined products						
Oral						
20-50 μg ΕΕ						
Norethisterone	G03AA01,G03AA03, G03AA05, G03AB04					
Levonorgestrel	G03AA07, G03AB03					
Norgestimate	G03AA11					
Desogestrel	G03AA09, G03AB05					
Gestodene	G03AA10, G03AB06					
Drospirenone	G03AA12					
CPA	G03HB01					
Natural estrogen						
Dienogest	G03AB					
NOMAC	G03AA14					
Non-oral						
Patch (norelgestromin)	G03AA13					
Vaginal ring (etonogestrel)	G02BB01					
Prog	gestin-only products					
Oral						
All progestogen only pills	G03AC01, G03AC02, G03AC03, G03AC09					
Non-oral						
Implant	G03AC08					
LNG-IUS	G02BA03					
MPA depot	G03DA02					

<sup>§</sup> EE=ethinylestradiol; CPA=cyproterone acetate; LNG-IUS=levonorgestrel intrauterine system; NOMAC=nomegestrol acetate; MPA=medroxyprogesterone acetate.

<sup>\*</sup> ATC=Anatomical Therapeutic Chemical classification.


**TABLE S3.** Included diagnoses of suicide an suicide attempt according to ICD-10

	Suicide	Suicide	attempt	
8th revision		E9500 to E9599		
10th revision	X6001	X6010	X7310	
	X6101	X6011	X7311	
	X6201	X6110	X7410	
	X6301	X6111	X7411	
	X6401	X6210	X7510	
	X6501	X6211	X7511	
	X6601	X6310	X7610	
	X6701	X6311	X7611	
	X6801	X6410	X7710	
	X6901	X6411	X7711	
	X7001	X6510	X7810	
	X7101	X6511	X7811	
	X7201	X6610	X7910	
	X7301	X6611	X7911	
	X7401	X6710	X8010	
	X7501	X6711	X8011	
	X7601	X6810	X8110	
	X7701	X6811	X8111	
	X7801	X6910	X8210	
	X7901	X6911	X8211	
	X8001	X7010	X8310	
	X8101	X7011	X8311	
	X8201	X7110	X8320	
	X8301	X7111	X8410	
	X8320	X7210	X8411	
	X8401	X7211	Z915A	


**TABLE S4.** Included diagnoses of venous thromboses from ICD-8 and ICD-10

	ICD-8	ICD-10	Diagnose
	450	1260, 1269	Pulmonary embolism
	438	1676	Sinus thrombosis
		1801	Thrombophlebitis in vena femoralis
	451.08	1802	Deep vein thrombosis in the legs
	451.00	1803	Unspecified deep vein thrombosis in the legs
		1808	Phlebitis a thrombophlebitis with other localization
Non pregnant		I808A	Phlebitis with other localization
rion prognam		1808B	Thrombophlebitis with other localization
		1808D	Phlebitis et thrombophlebitis venae jugularis
	452	I819	Thrombosis of the portal vein
	453.02	1822	Thrombosis or embolism in the vena cava
		1823	Thrombosis or embolism in the vena renalis
		1828	Thrombosis or embolism in other designated veins
	451.99	1829	Thrombosis or embolism in non-specified veins
		O087A	Phlebitis after extra-uterine pregnancy
		O087B	Phlebitis after molar pregnancy
		O087C	Phlebitis after abortion
		O087D	Thrombophlebitis after molar pregnancy
		O087E	Thrombophlebitis after extra-uterine pregnancy
		O087F	Thrombophlebitis after abortion
		O223	Phlebothrombosis profunda in graviditate
		O225	Thrombosis venae cerebri in graviditate
		O225A	Thrombosis sinuum venosum cerebri in graviditate
Pregnant		O228	Venous complications of pregnancy, others
rognant		O229	Venous complications of pregnancy without spec.
	671.01/02	O871	Thrombophlebitis profunda puerperalis
	671.03	O871A	Thrombophlebitis pelvis puerperalis
		O873	Thrombosis venae cerebri puerperalis
		O873A	Thrombosis sinuum venosum cerebri puerperalis
	671.08	O878	Venous complications in the puerperium, other
	671.09	O879	Venous complications in the puerperium without spec.
	634.59, 673.09	O880	Embolia aëris obstetrica
	673.19	O881	Embolia fluidi amniotici
	673.99	O882	Embolia obstetrica

FIGURE S1. Women fulfilling various inclusion and exclusion criteria



**FIGURE S2.** Lexis diagram: a cohort of women followed from age 15 through the period 1996–2013



**TABLE S5.** Hazard ratio of a first suicide attempt according to use of different types of hormonal contraception

Type of hormonal	Person	First suicide	Hazard ratio <sup>1</sup>	Hazard ratio <sup>2</sup>			
contraception	Years	attempt	[95% CL]	[95% CL]			
Never use	1,387,917	2,049	Reference	Reference			
All hormonal contraceptive	2,127,374	3,898	<b>1.82</b> [1.71-1.94]	<b>1.97</b> [1.85-2.10]			
Former use	405,527	1,052	<b>3.76</b> [3.45-4.11]	<b>3.40</b> [3.11-3.71]			
Combined products							
Oral							
All oral combined	1,983,435	3,528	<b>1.75</b> [1.64-1.87]	<b>1.91</b> [1.79-2.03]			
50 μg Ethinylestradiol							
Levonorgestrel	4,263	14	<b>3.04</b> [1.80-5.15]	<b>2.78</b> [1.64-4.71]			
20-40 µg Ethinylestradiol							
Norethisterone	10,824	31	<b>1.95</b> [1.37-2.79]	<b>2.03</b> [1.42-2.90]			
Levonorgestrel	175,565	267	<b>1.63</b> [1.43-1.87]	<b>1.81</b> [1.58-2.07]			
Norgestimate	168,046	307	<b>1.80</b> [1.59-2.04]	<b>1.92</b> [1.70-2.18]			
Desogestrel	477,965	855	<b>1.74</b> [1.60-1.90]	<b>1.89</b> [1.73-2.06]			
Gestodene	782,645	1,398	<b>1.73</b> [1.60-1.87]	<b>1.88</b> [1.74-2.03]			
Drospirenone	270,591	510	<b>1.83</b> [1.65-2.03]	<b>2.05</b> [1.85-2.27]			
Cyproterone acetate	89,051	141	<b>1.58</b> [1.33-1.88]	<b>1.81</b> [1.52-2.16]			
Non-oral							
Patch (norelgestromin)	5,302	19	<b>3.90</b> [2.48-6.14]	<b>3.28</b> [2.08-5.16]			
Vaginal ring (etonogestrel)	49,269	84	<b>2.34</b> [1.87-2.92]	<b>2.58</b> [2.06-3.22]			
	Progestin-	only products					
Oral							
All progestin only pills	38,965	62	<b>2.16</b> [1.67-2.79]	<b>2.29</b> [1.77-2.95]			
Norethisterone	13,236	27	<b>2.63</b> [1.79-3.85]	<b>2.77</b> [1.89-4.05]			
Desogestrel	25,580	35	<b>1.89</b> [1.35-2.64]	<b>2.01</b> [1.44-2.81]			
Non-oral							
Implants	18,291	107	<b>5.85</b> [4.80-7.13]	<b>4.42</b> [3.63-5.39]			
Levonorgestrel intrauterine system	25,789	38	<b>3.26</b> [2.35-4.52]	<b>2.86</b> [2.06-3.97]			
Medroxyprogesterone acetate	6,322	60	<b>10.2</b> [7.87-13.2]	<b>6.52</b> [5.03-8.46]			

<sup>1.</sup> Age as underlining time and adjusted for calendar year.


<sup>2.</sup> Additionally adjusted for education, polycystic ovary syndrome, and endometriosis.


**TABLE S6.** Hazard ratio of a first suicide attempt according to use of different types of hormonal contraception with 30-40  $\mu$ g levonorgestrel as reference and of progestogen only pills with all oral combined as reference

Type of hormonal	Person	First suicide	Hazard ratio <sup>1</sup>	Hazard ratio <sup>1</sup>
Contraception	Years	attempt	[95% CL]	[95% CL]
Oral				
All oral combined	1,983,435	3,528		Reference
50 μg Ethinylestradiol	_			
Levonorgestrel	4,263	14	1.53 [0.90-2.63]	
20-40 µg Ethinylestradiol	_			
Norethisterone	10824	31	1.12 [0.77-1.63]	
Levonorgestrel	175565	267	Reference	
Norgestimate	168046	307	1.06 [0.90-1.25]	
Desogestrel	477965	855	1.04 [0.91-1.20]	
Gestodene	782,645	1398	1.04 [0.91-1.18]	
Drospirenone	270,591	510	1.13 [0.97-1.31]	
Cyproterone acetate	89,051	141	1.00 [0.81-1.23]	
Non-oral				
Patch (norelgestromin)	5,302	19	<b>1.81</b> [1.14-2.89]	
Vaginal ring (etonogestrel)	49,269	84	<b>1.42</b> [1.11-1.82]	
	Progestin-or	nly products	3	
Oral				
All progestin only pills	38,965	62		1.20 [0.93-1.54]
Norethisterone	13,236	27	<b>1.53</b> [1.03-2.27]	
Desogestrel	25,580	35	1.11 [0.78-1.58]	
Non-oral				
Implants	18,291	107	<b>2.44</b> [1.95-3.06]	
Levonorgestrel intrauterine system	25,789	38	<b>1.58</b> [1.12-2.23]	
Medroxyprogesterone acetate	6,322	60	<b>3.60</b> [2.72-4.77]	

<sup>1.</sup> Age as underlining time and adjusted for calendar year, education, polycystic ovary syndrome, and endometriosis.

**FIGURE S3.** Quantitative bias analysis: Hazard ratio (HR) of suicide attempt as a function of the odds ratio (OR) of being a user of hormonal contraception, for prevalence of 33% of an unknown confounder in the population





OR for use of hormonal contraception for unknown confounder

The figure illustrates how much the calculated HR of originally 1.97 will change in case of an unidentified confounder that has a given OR for use of hormonal contraception (x-axis) and different hazard ratios of suicide attempt (y-axis). i.e, a factor implying a fivefold increase in use of hormonal contraception and have a HR of suicide of 6.8, will decrease the HR of suicide among users of hormonal contraception from the initial 1.97 to 1.0 (black curve).